Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 476Carcinoma, Non-Small-Cell Lung 233Breast Neoplasms 196Ovarian Neoplasms 171Glioblastoma 157Carcinoma, Hepatocellular 131Neoplasms 128Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 106Brain Neoplasms 98Lung Neoplasms 96Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 77Glioma 69Pancreatic Neoplasms 54Liver Neoplasms 44Melanoma 43Gliosarcoma 43Uterine Cervical Neoplasms 40Adenocarcinoma of Lung 39Stomach Neoplasms 37Recurrence 33Astrocytoma 30Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Triple Negative Breast Neoplasms 26Kidney Neoplasms 23Prostatic Neoplasms 22Esophageal Neoplasms 21

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Geriatric Assessment 1Exercise 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Neoplasm × Bevacizumab × Clear all
NCT01749384 2017-10-12

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡